Barclays raised the firm’s price target on Elevance Health (ELV) to $512 from $501 and keeps an Overweight rating on the shares post the Q4 report. The firm says it still struggles to understand 2025 Medicare Advantage enrollment growth comments and looks for a negative revision in the next cut of Centers for Medicare and Medicaid Services’ enrollment data.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health Reports Strong 2024 Results and Positive 2025 Outlook
- Morning Movers: GE Aerospace climbs after fourth quarter results
- Options Volatility and Implied Earnings Moves Today, January 23, 2025
- Elevance Health reports Q4 adjusted EPS $3.84, consensus $3.86
- Elevance Health sees FY25 adjusted EPS $34.15-$34.85, consensus $34.86